Principal Investigator
Wonseog Kim, MD, Ph.D
Samsung Medical Center
Total Trials
1
As PI
1
Completed
1
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
MIXED(2)
2 unique interventions1 categories
Analytics
Trial Phases
Phase 21
Trial Status
Completed1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell Lymphoma
PrincipalinvestigatorStart date: 2021-06-25
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Samsung Medical Center
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
3 similar investigators found
Chuanxu Liu, MD
Fudan University
1 trials
Shared therapeutic areas:
Natural Killer/T-cell Lymphoma
Similarity Score10%
Rong Tao, MD
Fudan University
5 trials
Shared therapeutic areas:
Natural Killer/T-cell Lymphoma
Similarity Score10%
Xuejun Ma, MD
Fudan University
1 trials
Shared therapeutic areas:
Natural Killer/T-cell Lymphoma
Similarity Score10%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell Lymphoma
All 1 trials loaded